SCHEDULE: RTW Investments Discloses 6.4% Stake in Cargo Therapeutics
Beneficial Ownership Disclosure (Schedule 13G Amendment)
RTW Investments and Roderick Wong have disclosed a 6.4% beneficial ownership stake in Cargo Therapeutics, Inc., holding over 3 million shares.
Summary
- RTW Investments, LP and Roderick Wong, M.D. collectively hold 3,055,063 shares of Cargo Therapeutics, Inc. common stock.
- This represents 6.4% of Cargo Therapeutics, Inc.'s outstanding common stock.
- The percentage is calculated based on 46,113,353 shares outstanding as of May 2, 2025, as reported in Cargo Therapeutics' Quarterly Report on Form 10-Q.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- RTW Investments, LP serves as an investment adviser to certain funds (the "RTW Funds") that directly hold the reported shares and shares issuable upon exercise of reported warrants.
- Roderick Wong, M.D. is the Managing Partner and Chief Investment Officer of RTW Investments.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance. The acquisition of a significant stake by an institutional investor can be viewed neutrally or slightly positively as a vote of confidence, but the filing itself is purely informational.
Positives
- A significant institutional investor, RTW Investments, has taken a substantial stake, potentially signaling confidence in Cargo Therapeutics' future prospects.
- The investment is stated to be in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive, long-term investment perspective.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by a specialized healthcare investment firm (RTW Investments) in a biotechnology company (Cargo Therapeutics). Such investments are common in the biotech sector, where specialized funds often take positions in companies with promising pipelines or technologies, signaling potential confidence in the company's long-term value.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor holding a 6.4% stake could be viewed positively, potentially increasing investor confidence and liquidity.
- Company Management: Awareness of a significant institutional holder may influence strategic decisions, though the filing states the investment is not for control.
Key Dates
| Date | Description |
|---|---|
| 2025-05-02 | Date as of which 46,113,353 shares outstanding were reported in Cargo Therapeutics' Quarterly Report on Form 10-Q. |
| 2025-05-08 | Date Cargo Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025. |
| 2025-06-30 | Date of event which required the filing of this statement (ownership threshold crossed or reporting period end). |
| 2025-08-14 | Date the Schedule 13G Amendment No. 2 was signed by RTW Investments, LP and Roderick Wong, M.D. |
Keywords
Cargo Therapeutics, RTW Investments, Roderick Wong, SEC filing, Schedule 13G, beneficial ownership, common stock, investment adviser, institutional investor, biotechnology, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.